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Abstract
Nitric oxide (NO) is an important mediator of host defence and of
vascular tone. In septic shock, upregulation of inducible NO
synthase leads to the production of vast amounts of NO, which
contribute to pathogen elimination but also to inappropriate vaso-
dilation and to loss of vascular resistance. Asymmetric dimethyl-
arginine (ADMA) is an endogenous inhibitor of NO synthases
shown to contribute to the regulation of vascular tone. ADMA was
recently identified as a marker of organ dysfunction and mortality in
intensive care patients and as a novel cardiovascular risk factor. In
the present issue of Critical Care, a study by O’Dwyer and
colleagues identifies ADMA as a potential regulator of NO
production in septic shock. Being an inhibitor of NO production,
ADMA may at least partly counteract pathological hypotension, but
at the same time may impair the NO-dependent host defence. A
mechanism is proposed by which the interplay between ADMA
and inducible NO synthase activity is mediated. ADMA levels
should be determined in future studies evaluating the regulation of
NO in the intensive care setting.
In the present issue of Critical Care, O’Dwyer and colleagues
[1] report the results of a study in 47 patients with septic
shock. Asymmetric dimethylarginine (ADMA) levels were
elevated in these patients at the time of admission to the
intensive care unit (ICU) as compared with a group of 10
healthy controls. ADMA levels in septic patients directly
correlated with the Sequential Organ Failure Assessment
scores, with the degree of acidaemia and lactaemia, and with
vasopressor requirements. Interestingly enough, ADMA levels
were higher in patients requiring vasoactive infusions than in
those not requiring vasoactive infusions. ADMA levels further
increased during the subsequent 7 days of ICU treatment.
Nonsurvivors tended to have higher ADMA plasma levels on
days 1 and 7 of ICU treatment as compared with survivors,
although this trend was insignificant in the small patient
group. The authors also demonstrated that a genetic
polymorphism in the promoter region of the dimethylarginine
dimethylaminohydrolase (DDAH) II gene was significantly
associated with ADMA levels in these patients, suggesting
that the genetically anchored dysfunction of the enzyme that
metabolises ADMA may importantly regulate ADMA levels.
Standard therapy for patients with sepsis includes ICU
admission, careful selection of antibiotic therapy, and, if
needed, haemodynamic and ventilatory support [2]. Despite
the use of these intensive therapies, however, mortality from
sepsis has remained at levels between 35% and 50% [2].
Nitric oxide (NO) is referred to as a key mediator of
vasodilatation and catecholamine resistance in septic shock
[3,4]. Whereas in physiological conditions NO is mainly
formed in the endothelium at low rates by the activity of the
constitutive, endothelial isoform of the enzyme NO synthase,
inflammatory stimuli such as bacterial lipopolysaccharides
and cytokines released during sepsis result in a strong
upregulation of an inducible isofom of NO synthase (iNOS).
This isoform, once upregulated, releases huge amounts of
NO during prolonged time intervals. The iNOS-derived NO
contributes to pathogen elimination. NO-induced vaso-
dilatation, however, also contributes to widespread vascular
loss of tone and has been implicated in the cardiovascular
failure in septic shock [5]. There has been controversy about
the pathophysiological roles of iNOS and NO in the
development of septic shock after a phase III trial with NG-
monomethyl-L-arginine, a nonselective NO synthase inhibitor,
resulted in excess mortality [6]. Indeed, experimental studies
have suggested that iNOS-derived NO plays an important
role in host defence and organ protection [7].
During the past decade knowledge has accumulated of
endogenous compounds that inhibit NO synthase activity,
and thereby regulate NO-dependent vascular function. The
major molecule endogenously present in the circulation at
concentrations sufficiently high to exert inhibitory effects on
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NO synthesis in vivo is ADMA. A structural analogue of
NG-monomethyl-L-arginine, the long-known NO synthase
inhibitor, and  of  L-arginine, ADMA is the endogenous
substrate of NO synthase (Figure 1). ADMA levels have been
shown to regulate NO generation, endothelial function, and
vascular resistance in animal models and in humans (for
recent reviews, see [8-10]). Moreover, ADMA has evolved
from prospective clinical trials as a novel cardiovascular risk
marker [11].
Previous evidence has linked elevated ADMA levels to
reduced kidney and liver function and to multiple organ failure
in ICU patients [12]. Moreover, prospective clinical data point
to the fact that ADMA may be a superior predictive marker of
ICU death [13]. We have recently shown that ADMA levels
are prospectively associated with organ dysfunction and with
the postoperative complication rate in patients undergoing
major elective surgery (unpublished data).
In the battle between the invading pathogen and the host
organism, NO generation has to be kept in a delicate balance
between ‘live’ (keeping NO within boundaries for cardio-
vascular homeostasis) and ‘let die’ (upregulating NO to a
sufficient degree for pathogen defence). Here, upregulation
of ADMA levels may be another long ignored but important
regulator.
But what may be the mechanism behind the interrelation of
iNOS activity and ADMA? Upregulation of iNOS leads to the
release of huge amounts of NO and superoxide, which, by
forming peroxynitrite, can nitrosylate proteins and thereby
damage tissues [14]. S-nitrosylation of DDAH II has been
shown to downregulate this enzyme’s activity, leading to
accumulation of ADMA [15]. This may explain why ADMA
levels were actually higher in patients with more vasopressor
need in the study by O’Dwyer and colleagues [1]: vaso-
pressor need identified patients with greater iNOS induction,
which, in turn, may have resulted in DDAH nitrosylation – and
thereby inactivation – which finally resulted in higher ADMA
levels that blocked the activities of both constitutive and
inducible NO synthases (Figure 2). Alternatively, compro-
mised kidney and liver function secondary to tissue
malperfusion may have led to reduced metabolic clearance of
ADMA by DDAHs [12,13]. The study did not, however, report
any data to support or refute any of these hypotheses. ADMA
may interfere, by nonspecific inhibition of NO synthases, with
critical physiological functions, eventually giving rise to a
cascade of organ dysfunction that may be fatal to the
critically ill patient [12].
With ADMA as a novel player in the game, understanding the
role of NO in the ‘live and let die’ issue of septic shock has
become even more complex. Measuring ADMA levels should
certainly be considered in future studies on NO in critically ill
patients.
Figure 1
Structural formulae. Schematic drawings of the structural formula of
(a) L-arginine, the natural substrate of nitric oxide (NO) synthase, (b)
NG-monomethyl-L-arginine, the NO synthase inhibitor used in clinical
trials, and (c) asymmetric dimethylarginine, the endogenous inhibitor of
NO synthases. The circle in (a) indicates the terminal guanidino
nitrogen group, where NO is cleaved by NO synthase.
Figure 2
Potential interrelation of nitric oxide generation and the
pathophysiology of sepsis. Potential interrelation of nitric oxide (NO)
generation by inducible nitric oxide synthase (iNOS) and by
asymmetric dimethylarginine (ADMA) and the pathophysiology of
sepsis. LPS, lipopolysaccharide; DDAH, dimethylarginine
dimethylaminohydrolase.Page 3 of 3
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